ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases
Sector: Electric Vehicles (EVs) • Location: Spain, Germany, Italy
Source: EU Funding & Tenders Portal
"In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. ISOS is designed to treat chronic diseases requiring lengthy treatments. The encapsulated GEB populations produce the therapeutic molec
- Status
- Under Construction
- Sector
- Electric Vehicles (EVs), Automotive, Manufacturing (Industrial)
- Location
- Spain
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | "In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. ISOS is designed to treat chronic diseases requiring lengthy treatments. The encapsulated GEB populations produce the therapeutic molecules ""on demand"", stimulated by the signals of the pathological environment within the patient, i.e., inflammation and/or reactive oxygen species. Bacteria populations interact among them to maintain a dynamic equilibrium of the GEB species and to guarantee the survival of the drug-producing GEB as long as the disease persists. The GEB ecosystem is designed in such a way that bacteria cannot survive outside of the encapsulating biomaterial, to meet future biosafety and regulatory requirements. The design and the configuration of the GEB ecosystem will be personalized for each patient, and it will be done using in-silico tools and synthetic biology. As a Proof-of-Concept, we propose to engineer an implantable GEB-based bioreactor for the therapy of the wet form of age-related macular degeneration (wAMD), which is caused by an abnormal production of Vascular Endothelial Growth factor (VEGF). This Proof-of-Concept will demonstrate the ability of ISOS to replace the repeated intraocular injections of Anti-VEGF molecules (current treatment) with a single ISOS bioreactor that will enhance the therapeutic response and minimize side effects due the molecular crosstalk between ISOS and the pathological environment. ISOS will establish the principles of a new generation of therapeutic products that will use recombinant probiotic bacteria strains libraries for personalized treatments with rigorous control of local drug production and efficient delivery based of dynamic variation of pathological signals." |
Location
Country | Spain |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Electric Vehicles (EVs), Automotive, Manufacturing (Industrial) |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Electric Vehicles (EVs) projects in Spain, Germany, Italy
- Electrodynamic Tether Technology for Passive Consumable-less Deorbit Kit
- On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology
- ACTIVATING INCLUSIVE GROWTH IN RAILWAY SMES BY WORKPLACE INNOVATION
- ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases
- Challenging the ICT Patent Framework for Responsible Innovation
